Published in Antimicrob Agents Chemother on July 22, 2016
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep (2000) 7.61
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health (1997) 3.48
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet (2001) 2.68
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med (2009) 2.64
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 2.09
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther (2012) 1.23
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2009) 1.21
Handbook of anti-tuberculosis agents. Introduction. Tuberculosis (Edinb) (2008) 1.18
GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models. Bioinformatics (2009) 1.17
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother (2008) 1.14
Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis (1999) 1.13
Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot (Tokyo) (1984) 1.12
Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis (2004) 1.11
Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos (1998) 1.10
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother (2000) 1.04
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol (2011) 1.03
Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol (2009) 1.03
Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob Agents Chemother (2005) 0.89
A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob Agents Chemother (2013) 0.86
In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. BMC Syst Biol (2015) 0.86
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother (2014) 0.85
Single-dose pharmacokinetics of rifapentine in elderly men. Pharm Res (1998) 0.85
A physiologically based pharmacokinetic model for capreomycin. Antimicrob Agents Chemother (2011) 0.84
Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. J Clin Pharmacol (1998) 0.84
Toxic nephritis with acute renal insufficiency caused by administration of capreomycin. Case report with necropsy findings. Dis Chest (1966) 0.83
Single-dose pharmacokinetics of rifapentine in women. J Pharmacokinet Biopharm (1998) 0.82
Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach. Eur J Drug Metab Pharmacokinet (2015) 0.81
Quantitative global sensitivity analysis of a biologically based dose-response pregnancy model for the thyroid endocrine system. Front Pharmacol (2015) 0.81
Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother (2014) 0.81
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother (2015) 0.80
Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis (2006) 0.79
Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model. J Pharmacokinet Pharmacodyn (2015) 0.78
Physiologically based pharmacokinetic/toxicokinetic modeling. Methods Mol Biol (2012) 0.78
A novel approach for estimating ingested dose associated with paracetamol overdose. Br J Clin Pharmacol (2015) 0.77